A new publication on NLX-112 further highlights its potential utility for treatment of dyskinesia (uncontrolled movements), a disturbing side effect of L-DOPA therapy in Parkinson's disease. NLX-112 was tested in parkinsonian macaques, a primate species that is highly predictive of response in human Parkinson's disease patients. When the macaques received NLX-112, their dyskinesia symptoms were  strongly reduced, confirming a previous study carried out in parkinsonian marmosets. Notably, NLX-112 did not interfere with the therapeutic movement facilitation produced by L-DOPA. Taken together, these results provide compelling support for testing NLX-112 in  Parkinson's disease patients. Safe and efficacious treatment of dyskinesia constitutes a clear medical need and NLX-112 could significantly improve the quality of life of Parkinson's disease patients. 

Full publication:  Depoortère et al. Parkinsonism and Related Disorders, vol. 78, p151-157, 2020

Newsletter

Please enable the javascript to submit this form

Follow Neurolixis on: